Kvapil M
Interni klinika 2. lekarske fakulty UK a FN Motol Praha.
Vnitr Lek. 2013 Aug;59(8):713-8.
The objective in developing a new type 2 diabetes therapy is to achieve greater safety and better efficacy. Newly registered drugs include lixisenatide, QW exenatide, dapagliflozin and insulin degludec. Once weekly gliptins and other substances are under development.